Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
- Weitere Titel
-
Behandlung mit einem 177Lutetium-radiomarkierten Liganden, der an das Prostata-spezifisches Membranantigen bei metastasiertem, kastrationsresistentem Prostatakrebs anbindet: Toxizität, Wirksamkeit und Überleben.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Technische Universität München, Dissertation, 2022
- Schlagwort
-
Prostatakrebs
Therapie
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der TU München
- (wann)
-
2022
- Urheber
-
Schwaiger, Sebastian Markus Emmo
- Beteiligte Personen und Organisationen
-
Heck, Matthias
Eiber, Matthias
- URN
-
urn:nbn:de:bvb:91-diss-20220915-1650213-1-7
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schwaiger, Sebastian Markus Emmo
- Heck, Matthias
- Eiber, Matthias
- Universitätsbibliothek der TU München
Entstanden
- 2022
Ähnliche Objekte (12)
18F-rhPSMA7 for biochemichal recurrence in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Application of PSMA-ligands in the uro-oncological theranostics framework : Novel methods to image and treat prostate cancer
Development of Radiohybrid PSMA Ligands for the Endoradiotherapy of Prostate Cancer
Genetically Engineered Membrane‐Coated Nanoparticles for Enhanced Prostate‐Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration‐Resistant Prostate Cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
18F-rhPSMA7 for biochemichal recurrence in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Application of PSMA-ligands in the uro-oncological theranostics framework : Novel methods to image and treat prostate cancer
Development of Radiohybrid PSMA Ligands for the Endoradiotherapy of Prostate Cancer
Genetically Engineered Membrane‐Coated Nanoparticles for Enhanced Prostate‐Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration‐Resistant Prostate Cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
18F-rhPSMA7 for biochemichal recurrence in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Application of PSMA-ligands in the uro-oncological theranostics framework : Novel methods to image and treat prostate cancer
Development of Radiohybrid PSMA Ligands for the Endoradiotherapy of Prostate Cancer
Genetically Engineered Membrane‐Coated Nanoparticles for Enhanced Prostate‐Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration‐Resistant Prostate Cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Effect of simvastatin on castration-resistant prostate cancer cells